The Diabetes Market Outlook To 2014: Market dynamics, competitive landscape, emerging therapies

Table of Contents

Executive summary

• Patient potential
• Global market analysis
• Pipeline analysis
• Leading players of the global diabetes market

Chapter 1 Scope and methodology

• Scope
• Methodology
• Scope of IMS data

Chapter 2 Patient potential

• Summary
• Introduction
• What is diabetes?
• Types of diabetes
• Type 1 diabetes
• Type 2 diabetes
• Gestational diabetes mellitus
• Impaired glucose tolerance
• Diabetic complications
• Epidemiology
• Diagnosis
• How is diabetes measured?
• Treatment algorithm
• Summary
• Introduction
• Market analysis by country
• Licensing trends
• Key events/trends in the diabetes market
• FDA' s revised guidelines on longer, larger cardiovascular risk studies for diabetes drugs
• Newer agents recommended by NICE in diabetes treatment
• A prophylactic treatment for children at high risk
• GSK discontinued development of remogliflozin
• Takeda' s Phase II loss of TAK-379
• Novo Nordisk' s Prandin lawsuit
• Market analysis by drug class
• Diabetes drug classes
• The insulin landscape
  • Human insulins
  • Animal insulins
• Drugs targeting underlying causes
  • Glitazones
  • Sulfonylurea
  • Biguanides
  • DPP-IV inhibitors
  • Alpha-glucosidase inhibitors
  • Glinides
  • Glucagon-like peptide-1 agonists
• DPP-IV and GLP-1 differences
• Insulin devices
• Insulin pump therapy
• Therapy area sales forecast
• Leading brands of the diabetes market
• Generic erosion among the leading brands
• Leading brands sales forecast

Chapter 4 Pipeline analysis

• Summary
• Introduction
• Emerging trends/key events in diabetes R&D
• Emerging therapies in the diabetes market
• Inhaled insulin still a distant reality
• Hitherto unexplored avenues in diabetes R&D: magnesium, chromium and
• vanadium
• SGLT-2 inhibitors yet to prove their potential
• Other novel mechanisms under development
• Profiles of key pipeline products
• Drugs under registration/recently approved
  • Victoza (liraglutide): Novo Nordisk
  • Onglyza (saxagliptin): BMS/AstraZeneca
  • SYR322 (alogliptin): Takeda
  • Byetta LAR (exenatide long-acting release): Eli Lilly, Amylin,
  • Alkermes
  • Syncria (albiglutide): GlaxoSmithKline
  • Ondero (linagliptin): Boehringer Ingelheim
  • R1583 (taspoglutide): Roche/Ipsen
  • AVE0010/ZP10: Sanofi-Aventis
  • BMS-512148 (dapagliflozin): AstraZeneca/BMS
  • Teplizumab: Eli Lilly/MacroGenics
• Competitive dynamics of the investigational drugs
• Key pipeline compounds sales forecast

Chapter 5 Leading players of the global

• diabetes market
• Summary
• Introduction
• Detailed analysis of the diabetes market players
• Novo Nordisk
  • Overview
  • Drug class focus
  • Marketed product portfolio
  • R&D pipeline analysis
  • Novo Nordisk: strategic growth analysis
• Takeda
  • Overview
  • Drug class focus
  • Marketed product portfolio
  • R&D pipeline analysis
  • Takeda: strategic growth analysis
• Sanofi-Aventis
  • Overview
  • Drug class focus
  • Marketed products portfolio
  • R&D pipeline analysis
  • Sanofi-Aventis: strategic growth analysis
• Eli Lilly
  • Overview
  • Drug class focus
  • Marketed products portfolio
  • R&D pipeline analysis
  • Eli Lilly: strategic growth analysis
• Merck & Co.
  • Overview
  • Drug class focus
  • Marketed products portfolio
  • R&D pipeline analysis
  • Merck: Strategic growth analysis
• Other major players in the diabetes market
• GSK
• Boehringer Ingelheim
• Leading players' outlook through to 2014

Chapter 6 Appendix

• IMS data
• Glossary
• Index

List of Figures

• Figure 2.1: Production of insulin and its action
• Figure 2.2: Diabetes treatment algorithm
• Figure 3.3: Global market sizes, 2008
• Figure 3.4: Global sales of types of diabetes brands ($m), 2008
• Figure 3.5: Relative positions of different types of insulins in the insulin market, 2008
• Figure 3.6: Relative positions of different diabetes drug classes, 2008
• Figure 4.7: Leading late-stage R&D products in the diabetes market, 2009
• Figure 5.8: Competitive dynamics of the top 10 diabetes players, 2007 - 08
• Figure 5.9: Drug class focus of Novo Nordisk, 2008
• Figure 5.10: Drug class focus of Takeda, 2008
• Figure 5.11: Drug class focus of Sanofi-Aventis, 2008
• Figure 5.12: Drug class focus of Eli Lilly, 2008
• Figure 5.13: Drug class focus of Merck, 2008

List of Tables

• Table 2.1: Estimated prevalence of diabetes mellitus across the seven major markets, 2008
• Table 2.2: Forecast prevalence of diabetes mellitus across the seven major markets, 2008 - 14
• Table 3.3: USA diabetes drug sales by ATC3 class, 2008 US$ millions
• Table 3.4: French diabetes drug sales by ATC3 class, 2008 US$ millions
• Table 3.5: German diabetes drug sales by ATC3 class, 2008 US$ millions
• Table 3.6: Italian diabetes drug sales by ATC3 class, 2008 US$ millions
• Table 3.7: Japanese diabetes drug sales by ATC3 class, 2008 US$ millions
• Table 3.8: Spanish diabetes drug sales by ATC3 class, 2008 US$ millions
• Table 3.9: UK diabetes drug sales by ATC3 class, 2008 US$ millions
• Table 3.10: Distribution of the global diabetes market by drug class, 2007 - 08
• Table 3.11: Characteristics of different types of insulin
• Table 3.12: Leading brands in the fast-acting insulin category, 2008
• Table 3.13: Characteristics of NovoRapid
• Table 3.14: Characteristics of Humalog
• Table 3.15: Leading brands in the long-acting insulin category, 2008
• Table 3.16: Characteristics of Lantus
• Table 3.17: Leading brands in the intermediate-acting insulin category, 2008
• Table 3.18: Characteristics of Protaphane HM
• Table 3.19: Leading brands in the intermediate- and fast-acting insulin category, 2008
• Table 3.20: Characteristics of NovoMix
• Table 3.21: Leading brands in the intermediate- and long-acting insulin category, 2008
• Table 3.22: Leading brands of the glitazones drug class, 2008
• Table 3.23: Leading brands of the sulfonylureas drug class, 2008
• Table 3.24: Leading brands of the biguanides drug class, 2008
• Table 3.25: Leading brands of the DPP-IV drug class, 2008
• Table 3.26: Strategic growth analysis of Januvia
• Table 3.27: Leading brands of the AGI drug class, 2008
• Table 3.28: Leading brands of the glinides drug class, 2008
• Table 3.29: Leading brands of the GLP-1 agonists drug class, 2008
• Table 3.30: Major differences between GLP-1 agonists and DPP-IV inhibitors
• Table 3.31: Diabetes market sales forecast by drug classes ($m),
• Table 3.32: Leading brands of the global diabetes market, 2008
• Table 3.33: Generic erosion index of key diabetes brands
• Table 3.34: Top 10 brands of the diabetes market, sales forecast 2008 - 14
• Table 4.35: Select late-stage diabetes R&D pipeline, 2008
• Table 4.36: An overview of Victoza
• Table 4.37: An overview of Onglyza
• Table 4.38: An overview of alogliptin
• Table 4.39: An overview of Byetta LAR
• Table 4.40: An overview of Syncria
• Table 4.41: An overview of Ondero
• Table 4.42: An overview of taspoglutide
• Table 4.43: An overview of AVE0010/ZP10
• Table 4.44: Ongoing Phase III trials of AVE0010/ZP10
• Table 4.45: An overview of dapagliflozin
• Table 4.46: Reduction in HbA1c on administering dapagliflozin
• Table 4.47: An overview of teplizumab
• Table 4.48: Key diabetes pipeline compounds sales forecast, 2008 - 14
• Table 5.49: Leading players of the diabetes market, 2008
• Table 5.50: Leading brands of Novo Nordisk, 2008
• Table 5.51: Key pipeline compounds of Novo Nordisk, 2008
• Table 5.52: Leading brands of Takeda, 2008
• Table 5.53: Key pipeline compounds of Takeda, 2008
• Table 5.54: Leading brands of Sanofi-Aventis, 2008
• Table 5.55: Key pipeline compounds of Sanofi-Aventis, 2008
• Table 5.56: Leading brands of Eli Lilly, 2008
• Table 5.57: Key pipeline compounds of Eli Lilly, 2008
• Table 5.58: Leading brands of Merck, 2008
• Table 5.59: Key pipeline compounds of Merck, 2008
• Table 5.60: Leading players in the diabetes market, sales forecast 2008 - 14